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Blood pressure (BP) in the prehypertensive range is
associated with an increased risk for cardiovascular (CV)
disease. Patients with co-morbidities are at greater risk for
chronic kidney disease (CKD) development in the presence
of prehypertension. Lifestyle changes can alter the natural
history of prehypertension; however, long-term adherence
is rare and thus, their impact on outcomes is limited.
Pharmacological therapy in patients with prehypertension
and demonstrable target organ damage with blockers of
the renin–angiotensin system has demonstrated benefits on
markers of CKD outcomes such as microalbuminuria. There
are no data, however, on ‘hard end points’ such as doubling
of creatinine or need for renal replacement therapy. In
patients with diabetes, monitoring changes in albuminuria,
along with assessment of BP in the prehypertensive range,
is important to optimize early management and impact the
attenuation of CKD progression. Data from natural history
studies in patients with type 1 diabetes indicate that
increases within the microalbuminuria range antedate
increases in BP within the prehypertensive range. Even
within the microalbuminuria range, however, systolic BP
increases above 125mmHg are predictive of nephropathy.
Thus, nephrologists need to ensure that their colleagues
appreciate the importance of not only early BP intervention
but also of monitoring albuminuria changes in order to have
maximal impact on CKD prevention.
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It is known that the relationship between the level of blood
pressure (BP) and the risk of cardiovascular (CV) disease
events is continuous, consistent, and independent of other
risk factors. Observational studies involving more than 1
million individuals indicate that death from both ischemic
heart disease and stroke increases linearly, starting at BP
levels as low as 115 mm Hg systolic and 75 mm Hg diastolic
upward.1 Epidemiological studies also support the hypothesis
that the level of BP and risk of chronic kidney disease (CKD)
progression is linear and extends into the normotensive
range.2,3
The term ‘prehypertension’ was selected by the Seventh
Report of the Joint National Committee on Prevention,
Detection, Evaluation, and Treatment of High BP to define a
group at higher CV risk with BP readings not previously
considered significant by clinicians.4 The range of BPs
defined as prehypertension is 120–139/80–89 mm Hg. This
range is based on two pieces of data: first, large epidemio-
logical studies, as previously mentioned and second, data
obtained from the focus groups of patients with hypertension
as gathered by members of the executive committee of the
Joint National Committee on Prevention, Detection, Evalua-
tion, and Treatment of High BP.1,4 The purpose of the focus
groups was to define a term that resonates with the populace
that would prompt them to ask for advice if they were told
that they were prehypertensive. The epidemiological analyses
provide evidence that the range of BPs defined as pre-
hypertension are associated with an intermediate level of CV
risk, higher than normotensive patients, that is, o120/
80 mm Hg but less than those with stage 1 hypertension, that
is, 4140/90 mm Hg.5
The data for prehypertension contributing to development
of CKD are weak. This review summarizes recent information
on prehypertension that is relevant for nephrologists. It
focuses on prehypertension as a CKD risk factor and its
potential contribution to progression of CKD.
PREHYPERTENSION AND CO-MORBIDITIES
The presence of prehypertension, especially in the range of
X130/80 mm Hg, is a harbinger of hypertension and risk of
developing hypertension that increases with age.4 Normo-
tensive individuals at 55–65 years of age have more than a
90% change of developing hypertension by age 80.4,6 Thus,
increases in BP are a reflection of advancing age as well as
development of co-morbid conditions, such as obesity and
min i rev iew http://www.kidney-international.org
& 2010 International Society of Nephrology
Received 2 August 2009; revised 27 August 2009; accepted 1 September
2009; published online 18 November 2009
Correspondence: George L. Bakris, Hypertensive Diseases Unit, Department
of Medicine, The University of Chicago Medical Center, 5841 S. Maryland
Avenue MC 1027, Chicago, Illinois 60637, USA. E-mail: gbakris@gmail.com
194 Kidney International (2010) 77, 194–200
diabetes. All of these conditions are known to accelerate
vascular aging by a variety of mechanisms, all converging on
nuclear factor-kB and discussed later in this paper.7–9
The prevalence of prehypertension is approximately
31–37% in the adult population of the United States, much
higher than hypertension, which is about 20%.10 Prehyper-
tension is most commonly associated with obesity and
metabolic syndrome,8,11 the risk factors also appreciated to
accelerate development and progression of CKD.8,10–14 A
marker of CKD progression, proteinuria, is 43–56% higher in
overweight and obese persons with nephropathy compared
with individuals with body mass index (BMI) o25 kg/m2.15
Moreover, there is epidemiological evidence from a large
cohort study that body mass index is the strongest predictor
of prehypertension in both men and women, relative to other
variables tested.16
The metabolic syndrome is an important factor in the
pathogenesis of CKD.11 However, it is a compilation of risk
factors that include hypertension, but not prehypertension.
Analyses of large databases show an association between
prehypertension, metabolic syndrome, and CKD, as well as
increased CV risk. Prehypertension alone, however, was not
found to increase the risk of CKD development.8,17,18 Data
from the Metabolic Syndrome in Active Subjects in Spain
Registry substudy further support this assertion. This
substudy shows that prehypertension is an insulin resistance
state and not the result of CKD.8 This suggests that
alterations of kidney function are a consequence rather than
a cause of elevated BP in the range of 120–139/80–89 mm Hg.
Thus, one must judge prehypertension by the company
it keeps.
Prehypertension is associated with a number of nontradi-
tional risk markers, all of which are associated with
endothelial dysfunction, accelerated vascular aging, and
increased CV risk. Some of these factors include micro-
albuminuria,12 C-reactive protein, serum tumor necrosis
factor-a, amyloid A, endothelin-1, homocysteine, advanced
glycation end products, and higher white blood cell counts.19
A commonly measured marker of kidney function is
microalbuminuria. It is a marker of endothelial dysfunction,
and an independent risk marker for CV events, and not a
marker of kidney disease as was previously thought.20
Increases in microalbuminuria over time, in the presence of
BP either remaining in the prehypertensive range or well
controlled, is associated with not only worsening endothelial
function but also with worsening kidney function.21
Many studies have tried to show a relationship between
blocking increases in microalbuminuria and prevention of
nephropathy. Blockers of the renin–angiotensin system are
frequently used to achieve this aim. Unfortunately, all of these
studies are confounded by reductions in BP, with none
showing true prevention of nephropathy independent of BP
reduction.20,22 Therefore, it is the prevention of BP rise that
would slow or prevent nephropathy progression and not
something specific to a drug class.23 This is not the case,
however, once advanced nephropathy with proteinuria is
present. In this setting of a BP being usually 4140/
90 mm Hg, BP reduction using blockers of the renin–
angiotensin system and ensuring maximal reductions in
proteinuria are associated with slower CKD progression.24
Prehypertension as a risk factor is relevant in the setting of
concomitant diseases associated with it as well as the age of
the patient. Recent data on aging show that mitochondrial
production of reactive oxygen species, innate immunity, the
local tumor necrosis factor-a-converting enzyme, and the
renin–-angiotensin system may underlie nuclear factor-kB
induction and endothelial activation in aged arteries. Thus,
multiple proinflammatory pathways converge on nuclear
factor-kB in the aged arterial wall, and transcriptional
activity of nuclear factor-kB is regulated by multiple nuclear
factors.25 This is an important observation as prehyperten-
sion, as part of the aging process, may simply be the
reflection of the magnitude of proinflammatory injury to
the vessel.
A review of the data dealing with inflammatory markers,
put into the perspective of vascular aging and prehyperten-
sion, notes that increased production of reactive oxygen
species observed in aging and hypertension may provide the
missing link interconnecting endothelin-1 and other inflam-
matory markers.7 These data are relevant to CKD progres-
sion, as the most common causes of CKD, diabetes, and
hypertension are diseases of accelerated vascular aging.
Hence, understanding these vascular changes in the context
of prehypertension as a marker of these changes is an
important first step in stopping CKD development associated
with these diseases.
Evidence to support prehypertension as a marker of target
organ injury comes from a cohort of adolescents with a high
prevalence of obesity and diabetes. In this cohort, prehy-
pertension was associated with increased cardiac output,
peripheral resistance index, and evidence of increased arterial
stiffness.26 This increase in arterial stiffness is associated with
a lower kidney function even within the normal reference
range and more importantly higher CV risk.27
PREHYPERTENSION AND CKD PROGRESSION
Epidemiologic evidence
The majority of information regarding CKD progression or
its development comes from advanced nephropathy studies
in people with hypertension.28 All of the studies dealing with
prehypertension, however, are epidemiological analyses of
large databases2,29–32 or small limited-outcome studies and
are summarized in Table 1. These epidemiological studies
have a range of follow-up between 7 and 21 years and show a
graded relationship between BP levels and the risk of CKD.
These studies are consistent, however, in that they indicate
that people with BP levels 4130/80 mm Hg over extended
periods of follow-up have between 11 and 90% risk of
worsening kidney function due to the prehypertension. It
should be noted that many of the people in these studies did
have concomitant risk factors, including hyperlipidemia and
other metabolic disturbances.
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A representative study to illustrate the relationship
between CKD risk and prehypertension comes from the
Multiple Risk Factor Intervention Trial. A clear relationship
between the level of systolic and diastolic pressure over a
16-year follow-up period provided important information in
the context of end-stage renal disease (ESRD) incidence.
Indeed, the increase in risk was noticeable across the
prehypertensive BP range with a 43.6% higher likelihood of
progressing to ESRD if it was in the 130–139/85–89 mm Hg
range versus the lower range (Figure 1). Overall, the relative
risk (RR) for the progression to ESRD related with any cause in
73,798 men, with baseline BPs of 4130/80 and o140/
90 mm Hg, was almost double, compared with optimal BP (RR
1.9, 95% confidence interval (CI) 1.4–2.7, Po0.001, Figure 1).2
Further support for the relationship between prehyperten-
sion and risk of ESRD comes from an analysis of the Kaiser
Permanente group in northern California. Investigators
evaluated 316,675 men and women who participated in
health check-ups between 1964 and 1985. In a subset of
128,270 subjects (40.5%) with BPs in prehypertensive range,
the adjusted RR for ESRD was significantly increased in both
groups with BPs between 120 to 129/80 and 84 mm Hg (RR
1.62, 95% CI 1.27–2.07) and 130 to 139/85 and 89 mm Hg
(RR 1.98, 95% CI 1.55–2.52), Figure 1),3 compared with
those with a BP ofo120/80 mm Hg. In addition, data from a
prospective cohort study of 158,365 Chinese men and women
over the age of 40 years,30 and the Physicians Health Study of
8093 healthy men without known kidney disease at baseline
support this observation. In the Physicians Health Study, 25.1%
of the total group (n¼ 2037) of men had BPs in the
prehypertensive range and this group had a 26% higher risk of
having an estimated glomerular filtration rate ofo60 ml/min per
1.73 m2 compared with those with a BP of o120/80 mm Hg.29
Taken together, these studies support the notion that BP
elevations above a systolic BP of 130 mm Hg is associated
with a higher risk of CKD development or progression. This
is further corroborated by data from the Kidney Early
Evaluation Program. In a recent analysis in which 88,559
participants were evaluated, 20,500 (23.1%) were in the
prehypertensive range. This analysis found that the greater
the systolic BP levels, even in the prehypertensive
range, 130–139 mm Hg, the greater is the probability of
Table 1 | Epidemiological studies of CKD/ESRD risk and prehypertension
Study
No. of subjects
in the study
No. of subjects with
prehypertension
Years or person-
years of follow-up
Blood pressure
levels Risk of CKD Final event
MRFIT study2 332,544 men 73,798 men 16 years follow-up 130–139/
80–89mmHg
RR 1.9 (95% CI 1.4–2.7)
Po0.001
Incidence of
ESRD
Hsu et al.3 316,675 men
and women
128,270 men and
women
21 years/8,210,431
person-years
BP 120–129/
80–84mmHg
BP 130–139/
85–89mmHg
RR 1.62 (95% CI 1.27–2.07)
RR 1.98 (95% CI 1.55–2.52)
Po0.05
Incidence of
ESRD
Physicians Health
Study29
8093 men 2037 men 14 years follow-up SBP 130–139mmHg OR 1.26 (95% CI 1.03–1.53)
Po0.002
CKD
Reynolds et al.30 158,365 men
and women
54,654 men and
women
1,236,422 person-
years follow-up
SBP 120–139mmHg
DBP 80–89mmHg
HR 1.30 (95% CI 0.98–1.74)
Po0.001
Incidence of
ESRD
CLUE study32 23,534 men
and women
20 years Men
o120/80mmHg
130–139/
80–89mmHg
Women
o120/80mmHg
130–139/
80–89mmHg
HR 1.4 (95% CI 0.2–12.1)
HR 3.3 (95% CI 0.4–25.6)
HR 2.5 (95% CI 0.05–12.0)
HR 3 (95% CI 0.6–14.4)
P=NS
CKD
Obermay et al.31 17,375 men
and women
B70% with normal BP
and prehypertension
7 years Prehypertension OR 1.11 (95% CI 0.89–1.31)
P=NS
CKD
Abbreviations: CI, confidence interval; CKD, chronic kidney disease, glomerular filtration rate o60ml/min per 1.72m2 using the abbreviated Modification of Diet in Renal
Disease; DBP, diastolic blood pressure; ESRD, end-stage renal disease, as recipient of renal transplantation or maintenance dialysis; HR, hazard ratio; MRFIT, Multiple Risk Factor
Intervention Trial; NS, not significant; OR, odds ratio; RR; risk reduction; SBP, systolic blood pressure.
46.3% higher risk*
MRFIT study
Hsu et al. study
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Figure 1 |Age-adjusted rates of end-stage renal disease
(ESRD) for prehypertension in the Multiple Risk Factor
Intervention Trial (MRFIT) and Hsu et al.3 analyses. *Between
the MRFIT prehypertensive cohorts, the risk for ESRD
development was increased.
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CKD being present (20% at o130 mm Hg, 28.5% at
130–139 mm Hg, Po0.001), a relationship that held
regardless of race or sex.33
It is clear that the relationship between prehypertension
and CKD is weak, as smaller and shorter-term studies fail to
show this association. A community-based, observational
study of 23,534 people, followed for 20 years to evaluate CKD
risk, found that the RR of developing CKD among those with
high normal BP levels was 3.3 (95% CI 0.4–25.6) for men
compared with individuals with optimal BP and 3.0 (95% CI
0.6–14.4) for women. The associations of high normal neared
statistical significance (P¼ 0.075).32 A second longitudinal
cohort study of 17,375 apparently healthy volunteers in
Vienna, followed for a median of 7 years to evaluate the
relationship between prehypertension and CKD, showed
similar findings with the aforementioned study.31 Both these
studies had very wide confidence intervals and helped to
make the point that the associations between prehyperten-
sion and CKD risk are present but weak. As has been noted in
many analysis, it is the presence of concomitant metabolic
derangements that contributes to CKD development in
addition to prehypertension.8,11
Studies in pre-existing conditions, such as diabetes,
provide stronger data about the relationship of prehyperten-
sion and CKD risk. In a population-based sample of adults
with type I diabetes, lower BPs were protective against
incident proteinuria and incident estimated glomerular
filtration rate reductions to o60 ml/min per 1.73 m2. The
maximum protective effect for both of these kidney disease-
related outcomes was observed at BP levels of o120/
80 mm Hg.34 In this study, those with a systolic BP between
120 and 129 mm Hg had a lower 16-year cumulative
incidence of proteinuria, 0.76 (95% CI 0.53–1.09) compared
with those with a systolic BP of 4130 mm Hg (Po0.0001).34
Lastly, data from 137 patients with type I diabetes in
Denmark showed that increases in systolic BP above
125 mm Hg predicted development of nephropathy.35 More-
over, it is established that people with type I diabetes with BP
increases into the high prehypertensive range and who have
increases in albuminuria from baseline, are more likely to
have CKD progression. In the Diabetes Control and
Complication trial, 19 of 21 (90%) progressors reached
clinical diabetic nephropathy before the diagnosis of
hypertension was made, that is, 4140/90 mm Hg. In the
intensive glycemic treatment group, the rise in diastolic BP
preceded the rise in albuminuria by 1 to 2 years. Intensively
treated progressors who developed hypertension did so
before developing albuminuria, that is, 4300 mg/day. Thus,
in high-risk CKD patients, both the change in albuminuria
within the microalbuminuria range and BP within the
prehypertensive range need to be monitored.36
PREHYPERTENSION AND HISTOLOGICAL EVIDENCE OF CKD
Data on the relationship between changes in mesangial
proliferation and the degree of renal arteriolar hyalinosis
within the prehypertensive range are limited to only a few
diseases. Diabetes and immunoglobulin A nephropathy have
data showing changes in mesangial proliferation and degree
of arteriolar hyalinosis in the prehypertensive range. Diabetes
is confounded by glycemic effects on tissue; therefore, data
evaluating vascular changes in type I diabetes, the best model
to assess prehypertensive changes, are not very revealing.
Immunoglobulin A nephropathy, being an immunologically
mediated disease, may provide more insight.
A study of 332 consecutive renal biopsy specimens,
coupled with clinical data from patients with immunoglo-
bulin A nephropathy, describe changes in mesangial pro-
liferation and arteriolar hyalinosis affecting the interlobular
artery that correlated with BP levels in the prehypertensive
range. A greater degree of mesangial proliferation and
arteriolar hyalinosis was noted in prehypertensive range of
o140/90 mm Hg, whereas no changes were noted among
those with an optimal BP ofo120/80 mm Hg.37 In a separate
study by Hisayama et al.,38 652 consecutive population-based
autopsy samples without hypertension treatment were
evaluated before death. The relationship between the severity
of renal arteriosclerosis and BP levels was classified according
to the Joint National Committee on Prevention, Detection,
Evaluation, and Treatment of High BP. Both hypertensive and
prehypertensive subjects, after adjustment for age and gender,
had significantly higher frequencies of renal arteriosclerosis
than subjects with normal BP (normal 11.9%; prehyperten-
sion 28.5%; stage 1 hypertension 32.9%; stage 2 hypertension
58.2%). In a logistic regression model, those with prehyper-
tension had a higher incidence of renal arteriosclerosis and
arteriolar hyalinosis after adjustment for other CV risk
factors. This significant association was observed across renal
arterial vasculature.38
Taken together, these data support the following concepts.
First, increases in BP over time within the prehypertensive
range are associated with morphological changes within the
kidney as well as the behavior of the endothelium. Second,
increases in albuminuria parallel BP increases and can
antedate development of hypertension in type I diabetes. This
is generally not the case in type II diabetes. Lastly, from natural
history studies in type I diabetes performed by Mogensen
(Mogensen, personal communication), it is clear that increases
in systolic BP to levels 4125 mm Hg are associated with
development of nephropathy. Interestingly, only approxi-
mately 30% of the people studied by this group developed
increases in pressure; this is the incidence of nephropathy in
type I diabetes.35,39 Recent findings of candidate genes that
identify patients with diabetes as high risk for nephropathy
may also affect BP changes.40 Whether this susceptibility is
mediated by changes within the kidney or emanate from the
endothelium throughout the body is unknown.
MANAGEMENT OF PREHYPERTENSION
The current data support lifestyle intervention as the
cornerstone of therapy for the general population: weight
reduction to maintain normal body weight (body mass index
18.5–24.9), adopting the Dietary Approaches to Stop
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Hypertension plan, reducing sodium intake to o100 mEq/l
(2.4 g sodium or 6 g sodium chloride), increasing physical
activity (at least 30 min per day, most days of the week), and
limiting alcohol consumption to under 1 oz or 30 ml
ethanol.4 These interventions have all been shown to reduce
the risk of BP increases over time.
Evidence of the success of lifestyle modifications come
from trials such as PREMIER, conducted in 810 adult
participants volunteers with prehypertension or stage 1
hypertension to assess the effect of a behavioral intervention
on BP. The intervention groups were successful in reducing
BP and the prevalence of hypertension at 6 months. In the
18-month intervention, participants in both behavioral
intervention groups had less hypertension, more weight loss,
and better reduction in sodium and fat intake than those
receiving only advice. However, the differences were not
statistically significant.41 Physicians were more likely to
recommend lifestyle modifications to obese people, even
though they were neither more nor less likely to adhere to the
advice than those with normal weight. Furthermore,
individuals were less likely to follow advice on exercise and
weight loss than sodium and alcohol restriction.42
A few things are clear from all lifestyle intervention
studies; they are effective for delaying the onset of hyperten-
sion in the short term, up to 1 year, but then there is
regression to the mean. This is true for all studies of lifestyle
modification, including weight loss studies as well as those
requiring major decision making on the part of the patient.
Thus, only a minority of individuals adhere to lifestyle
recommendations derived from trials, as evidenced by obesity
and diabetes being international epidemics.43 Moreover,
nephrologists rarely see these patients early in their natural
history. It is noteworthy that there are no such lifestyle
interventions in early CKD, although because sustained
increases in BP over time are well known to contribute to
CKD progression, one could assume that keeping BP from
rising with an exercise, low sodium lifestyle would be
beneficial for preserving kidney function.
PHARMACOLOGICAL MANAGEMENT
There are very few trials that examine interventions to alter
the natural history of disease within the prehypertensive
range. No study has tested an intervention in this BP range to
evaluate change in kidney function in the general population,
although a recent study has examined this in early type I
diabetic nephropathy and is discussed later in this section.44
The only trial that evaluated the natural history of
hypertension in a general context was The TRial Of
Preventing Hypertension. This was a randomized, placebo-
controlled, double-blinded clinical trial designed to evaluate
whether 2 years of treatment with the angiotensin receptor
blocker candesartan cilexetil at 16 mg daily alters the natural
history of hypertension development. A total of 809
individuals were randomly assigned to placebo or low-dose
candesartan cilexitil for 2 years, followed by 2 years of
placebo. The trail showed that pharmacological treatment
can prevent or postpone the development of hypertension,
with a 66.3% reduction in hypertension incidence relative to
placebo over the first 2 years and a 26.8% absolute reduction
at the end of 2 years. Over all 4 years, there was a 15.6%
reduction in hypertension incidence relative to placebo and a
9.8% absolute reduction.45 The benefit of a lower BP over a
longer time period was evident in the active treatment group,
although there was some regression to the mean over the
ensuing 2 years when patients were switched to placebo.
Perhaps, the majority of studies evaluate changes in the
prehypertensive range in the setting of diabetes. More than
30 years ago, Marre et al.46 showed that in normotensive
patients with type I diabetes (baseline BP 137/82 mm Hg), a
reduction in BP with an angiotensin-converting enzyme
inhibitor, enalapril, 20 mg/day for 6 months reduced
persistent microalbuminuria,46 but there were no data on
nephropathy progression. More recently, a multicenter,
controlled trial involving 285 normotensive patients with
type I diabetes and normoalbuminuria by Mauer et al.44
randomly assigned patients to receive losartan (100 mg
daily), enalapril (20 mg daily), or placebo for 5 years. The
primary end point was a change in the fraction of glomerular
volume occupied by mesangium in kidney-biopsy specimens.
The researchers noted no difference in mesangial fractional
volume per glomerulus over the 5-year period between the
placebo group (0.016 units) and either of the treatment
groups. These changes were independent of differences in BP
among the groups. Thus, they concluded that early blockade
of the renin–angiotensin system in patients with type I
diabetes did not slow nephropathy progression but slowed
the progression of retinopathy. These data, taken together
with outcome data, suggest that the effects of early
pharmacological intervention even in early type I diabetes
are not warranted beyond good glycemic and lipid manage-
ment to slow nephropathy.
Interventions in type II diabetes, however, may be
different (Table 2). The Appropriate Blood pressure Control
in Diabetes ABCD trial examined the progression of
nephropathy over a 5-year period, comparing intensive usual
BP control in patients with type II diabetes. The unique
intervention in this trial is that all patients were normoten-
sive. The lower BP groups with an achieved systolic BP of
o130/mm Hg showed slowed progression to incipient and
overt diabetic nephropathy, decreased progression of diabetic
retinopathy, and diminished incidence of stroke.47
More recent evidence shows the effect of active treatment
on CKD outcomes in the Action in Diabetes and Vascular
disease Controlled Evaluation study. The data from this large
trial in patients with predominantly stage 1 hypertension
showed slowing of CKD development independent of the
initial BP levels, even if within the normotensive range of
o120/70 mm Hg. Moreover, those who were able to achieve a
systolic BP level of o110 mm Hg systolic and 65 mm Hg
diastolic have the greatest slowing of CKD.48 This trial further
supports the notion of treating BP much earlier in the disease
course to possibly stop nephropathy progression.
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CONCLUSION
Those with prehypertension have an increased risk for CV
disease. The totality of the evidence, largely from epidemio-
logical studies, illustrates that BP in the prehypertensive range
influences CKD progression but only to a minor extent. Its
effect takes on greater relevance when present with con-
comitant metabolic risk factors or with target organ injury,
especially in older patients. Studies of 45 years would be
needed to fully assess the effect of prehypertension on CKD
progression; however, given the current guideline recommen-
dations for CV risk reduction coupled with early observations
of Mogensens’ group of more than two decades of follow-up
(personal communication), it is highly unlikely that anyone
whose systolic BP remains below 130 mm Hg even without
treatment is at risk for clinical nephropathy and certainly not
ESRD. Given that nephrologists rarely see patients with
prehypertension, they should be aware that pharmacological
intervention at levels above a BP of 130/80 mm Hg will not
dramatically alter nephropathy progression in people with
normo or microalbuminuria, based on recent prospective
data. One could speculate that the results might be more
dramatic among those with albuminuria levels of 4200 mg/
day, as this has universally been the case in outcome studies.24
Individuals with target organ damage evidenced by albumi-
nuria or elevated creatinine would be excellent candidates for
drug therapy involving agents that block the renin–angioten-
sin system if their BP was in the prehypertensive range.
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